Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 113 results found. Search for [ COVAXIN trial ]

Results 1 to 21 of 113
BusinessToday.In
November 23, 2020
The panel-led by Dravida Munnetra Kazhagam (DMK) lawmaker Kanimozhi Karunanidhi will hear officials of pharmaceutical departments on the status of the COVID-19 vaccine


BusinessToday.In
November 23, 2020
Coronavirus vaccine update: Adar Poonawalla, the CEO of Serum Institute had recently said that his company might sell a two-shot COVID-19 vaccine for around Rs 500-600 for the general public


BusinessToday.In
November 23, 2020
The Prime Minister is expected to hold two back-to-back meetings, one with those states with high caseloads and another related to vaccine distribution strategy.


BusinessToday.In
November 22, 2020
Bharat Biotech has started the phase- 3 trial of its potential COVID-19 vaccine, involving 26,000 volunteers this month across 25 centres in the country, including Hyderabad, Goa, Nagpur, Bhubaneswar, and Aligarh


Reuters
November 22, 2020
On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose


Joe C Mathew
November 21, 2020
\"We expect emergency authorisation for Oxford-Astrazeneca vaccine to be sought in the UK. If so, it will give an opportunity for India regulator also (to consider such an option),\" says Dr Vinod Paul, chairman of the National Expert Group on Vaccine Administration for COVID-19


BusinessToday.In
November 21, 2020
Bharat Biotech, the developer of India's indigenous vaccine Covaxin, has said that it is planning to enrol about 2,000 participants each in metros for Phase-3 trials of its COVID-19 vaccine that began earlier this week


Reuters
November 17, 2020
The Hyderabad-based firm initiated phase I and phase II trials of its vaccine candidate after getting the green signal from the Drugs Controller General of India


PTI
November 16, 2020
Speaking virtually at a programme organised by the Indian School of Business, Ella said the company is also working on another vaccine for COVID-19 which would be in the form of nasal drops and can be ready by next year


BusinessToday.In
November 15, 2020
As per Anthony Fauchi, the Pfizer's vaccine distribution process in the US will start in December. This, he said, will also help reduce the daily spike in coronavirus cases, which reached 1.9 lakh this week


Anwesha Madhukalya
November 12, 2020
Nirmala Sitharaman press conference: The minister said that the Rs 900 crore funding to the Department of Biotechnology will be for research purposes only


BusinessToday.In
November 11, 2020
COVAXIN's phase-3 trial at AMU is aimed at checking the safety and effectiveness of the COVID-19 vaccine, jointly developed by the Hyderabad-headquartered Bharat Biotech, National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR)


BusinessToday.In
November 11, 2020
Coronavirus vaccine: India will focus on these two vaccines as they are being tested on the Indian population and hence has a major advantage over other potential candidates


BusinessToday.In
November 10, 2020
Share of Pfizer gained 19.46% to touch record high of Rs 5875 against previous close of Rs 4917 on BSE


BusinessToday.In
November 10, 2020
Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology, was registered by the Russian Health Ministry


BusinessToday.In
November 7, 2020
India may concentrate its efforts on Bharat Biotech's Covaxin as AstraZeneca's COVID-19 vaccine deliveries may be delayed. The months of November and December could be critical in terms of vaccine availability as a number of companies are likely to publish late-stage trial data


Reuters
November 5, 2020
The company has taken on the development of Oxford University's potential COVID-19 vaccine, scoring billions in funding and signing multiple deals to supply over three billion doses to countries around the world


BusinessToday.In
November 5, 2020
The Hyderabad-based company that has developed COVAXIN with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV), had hoped to roll it out in the second quarter of 2021


BusinessToday.In
November 5, 2020
Coronavirus vaccine update: Data compiled by Duke Global Health Innovation Center said that India has pre-ordered 600 million doses of coronavirus vaccine and is now in the process of negotiation for additional 1 billion doses


BusinessToday.In
November 4, 2020
COVID-19 vaccine update: Based on the success of the trials and regulatory approvals, we can expect vaccine to be available in India by January 2021, only if its proven immunogenic and efficacious, says SII CEO Adar Poonawalla


PAGES 1 OF 6  12345